Introduction - The coxib controversies

Inflammopharmacology

Volumn 13, Issue 4, 2005, Pages 331-341

  Rainsford, K D ^a  

^a SHEFFIELD HALLAM UNIVERSITY   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

BENOXAPROFEN; CELECOXIB; CYCLOOXYGENASE 2 INHIBITOR; DICLOFENAC; DISEASE MODIFYING ANTIRHEUMATIC DRUG; IBUPROFEN; NAPROXEN; NON PRESCRIPTION DRUG; NONSTEROID ANTIINFLAMMATORY AGENT; ROFECOXIB; VALDECOXIB;

ACUTE KIDNEY FAILURE; ANTIINFLAMMATORY ACTIVITY; CARDIOTOXICITY; CARDIOVASCULAR RISK; CORONARY ARTERY BYPASS GRAFT; DOSE CALCULATION; DRUG ACCUMULATION; DRUG ELIMINATION; DRUG HALF LIFE; DRUG MARKETING; DRUG MEGADOSE; DRUG MONITORING; DRUG RESEARCH; DRUG SAFETY; DRUG SURVEILLANCE PROGRAM; DRUG WITHDRAWAL; FOOD AND DRUG ADMINISTRATION; GASTROINTESTINAL TOXICITY; HUMAN; HYPERTENSION; INTERSTITIAL NEPHRITIS; LIVER TOXICITY; MACULA DENSA; NEPHROTOXICITY; PEER REVIEW; PERIPHERAL EDEMA; PRIORITY JOURNAL; REVIEW; RHEUMATIC DISEASE; RISK ASSESSMENT; RISK MANAGEMENT; SYSTOLIC BLOOD PRESSURE; TREATMENT CONTRAINDICATION;

ANIMALS; CARDIOVASCULAR DISEASES; CYCLOOXYGENASE 2 INHIBITORS; HUMANS; LACTONES; SULFONES;

EID: 27744593934     PISSN: 09254692     EISSN: None     Source Type: Journal    
DOI: 10.1163/156856005774415628     Document Type: Review

References (80)

1. Ahmad, S. R., Kortepeter, C., Brinker, A., et al. (2002). Renal failure associated with the use of celecoxib and rofecoxib, Drug Safety 25, 537-544.
2. American College of Rheumatology, Hotline (2005). The safety of COX-2 inhibitors. Deliberations from the Februrary 16-18, 2005, FDA meeting. ACR Hotline. Accessible online at http://www.rheumatology.org
3. Anonymous (2002). Cardiovascular adverse effects of coxibs, Prescrire Int. 11, 181-182.
4. Aw, T. J., Haas, S. J., Liew, D., et al. (2005). Meta-analysis of cyclooxygenase-2 inhibitors and their effects on blood pressure, Arch. Intern. Med. 165, 490-496.
5. Bjarnason, I. and Rainsford, K. D. (2001a). Are cyclooxygenase 2 inhibitors free of gastrointestinal side effects?, West. J. Med. 175, 267-268.
6. Bjarnason, I. and Rainsford, K. D. (2001b). COX-2 inhibitors and the gastrointestinal tract. Gut 48, 451.
7. Brater, D. C. (1999). Effects of nonsteroidal anti-inflammatory drugs on renal function: focus on cyclooxygenase-2-selective inhibition, Am. J. Med. 107, 65S-70S.
8. Brater, D. C. (2002). Anti-inflammatory agents and renal function, Semin. Arthritis Rheum. 32 (Suppl. 1), 33-42.
9. Bresalier, R. S., Sandler, R. S., Quan, H., et al. (2005). Cardiovascular events associated with rofecoxib in a colorectal adenoma chemoprevention trial, N. Engl. J. Med. 352, 1092-1102.
10. Blinker, A., Goldkind, L., Bonnel, R., et al. (2004). Spontaneous reports of hypertension leading to hospitalisation in association with rofecoxib, celecoxib, nabumetone and oxaprozin, Drugs Aging 21, 479-484.
11. Boyd, I. W., Mathew, T. H. and Thomas, M. C. (2000). COX-2 inhibitors and renal failure: the triple whammy revisited, Med. J. Austr. 173, 274.
12. Buchanan, W. W. and Kean, W. F. (2002). Osteoarthritis IV: Clinical therapeutic trials and treatment, Inflammopharmacology 10, 79-155.
13. Buscarini, L. (1996). Anti-inflammatory analgesics and drugs used in gout, in: Meyler's Side Effects of Drugs., 13th edn, Dukes, M. N. G. (Ed.), pp. 204-264. Elsevier, Amsterdam.
14. Cannon, G. W., Caldwell, J. R., Holt, P., et al. (2000). Rofecoxib, a specific inhibitor of cyclooxygenase 2, with clinical efficacy comparable with that of diclofenac sodium: results of a one-year, randomized, clinical trial in patients with osteoarthritis of the knee and hip. Rofecoxib Phase III Protocol 035 Study Group, Arthritis Rheum. 43, 978-987.
15. D'Arcy, P. F. (1982). Drug reactions and interactions in the elderly patient, Drug Intell. Clin. Pharm. 16, 925-929.
16. Dhaun, N., Maxwell, S. R. J. and Webb, D. J. (2005). Rofecoxib, selective COX-2 inhibitors and cardiovascular risk, J. Roy. Coll. Phys. Edin. 35, 101-103.
17. Drazen, J. M. (2004). COX-2 inhibitors - a lesson in unexpected problems, N. Engl. J. Med. 352, 1131-1132.
18. Emery, P., Zeidler, H., Kvien, T. K., et al. (1999). Celecoxib versus diclofenac in long-term management of rheumatoid arthritis: randomised double-blind comparison, Lancet 354, 2106-2111.
19. Esteve, J. B., Launay-Vacher, V., Brocheriou, I., et al. (2005). COX-2 inhibitors and acute interstitial nephritis: case report and review of the literature, Clin. Nephrol. 63, 385-389.
20. Feldman, M. and McMahon, A. T. (2000). Do cyclooxygenase-2 inhibitors provide benefits similar to those of traditional nonsteroidal anti-inflammatory drugs, with less gastrointestinal toxicity?, Ann. Intern. Med. 132, 134-143.
21. FitzGerald, G. A. (2004). Coxibs and cardiovascular disease, N. Engl. J. Med. 351, 1709-1711.
22. Fowles, R. E. (2003). Potential cardiovascular effects of COX-2 selective nonsteroidal antiinflammatory drugs, J. Pain Palliat. Care Pharmacother. 17, 27-50.
23. Graham, G. G., Graham, R. I. and Day, R. O. (2002). Comparative analgesia, cardiovascular and renal effects of celecoxib, rofecoxib and acetaminophen (paracetamol), Curr. Pharm. Des. 8, 1063-1075.
24. Halter, F., Rainsford, K. D., Sirko, S. P., et al. (1997a). NSAID-induced mucosal injury: analysis of gastric toxicity of new generation NSAIDs; ulcerogenicity compared with ulcer healing, Yale J. Biol. Med. 70, 33-43.
25. Halter, F., Peskar, B., Rainsford, K. D., et al. (1997b). Cytoprotection and healing: two unequal brethren, Inflammopharmacology 5, 407-414.
26. Hankey, G. J. and Eikelboom, J. W. (2003). Cyclooxygenase-2 inhibitors: are they really atherothrombotic, and if not, why not?, Stroke 34, 2736-2740.
27. Harris Jr., R. C. (2002). Cyclooxygenase-2 inhibition and renal physiology, Am. J. Cardiol. 89 (6A), 10D-17D.
28. Hawkey, C. J. (1999). COX-2 inhibitors, Lancet 353, 307-314.
29. James, M. J. and Cleland, L. G. (2004). Applying a research ethics committee approach to a medical practice controversy: the case of the selective COX-2 inhibitor rofecoxib, J. Med. Ethics 30, 182-184.
30. Juni, P., Rutjes, A. W. S. and Dieppe, P. A. (2002). Are selective COX 2 inhibitors superior to traditional non steroidal anti-inflammatory drugs?, Br. Med. J. 324, 1287-1288.
31. Juni, P., Nartey, L., Reichenbach, S., et al. (2004). Risk of cardiovascular events and rofecoxib: cumulative meta-analysis, Lancet 364, 2021-2029.
32. Laine, L. (2002). The gastrointestinal effects of nonselective NSAIDs and COX-2-selective inhibitors, Semin. Arthritis Rheum. 32 (3 Suppl. 1), 25-32.
33. Laine, L. (2004). Proton pump inhibitor co-therapy with nonsteroidal anti-inflammatory drugs - nice or necessary?, Rev. Gastroenterol. Disord. 4 (Suppl. 4), S33-S41.
34. Langman, M. J., Jensen, D. M., Watson, D. J., et al. (1999). Adverse upper gastrointestinal effects of rofecoxib compared with NSAIDs, J. Am. Med. Ass. 282, 1929-1933.
35. Langten, P. E., Hankey, G. J. and Eikelboom, J. W. (2004). Cardiovascular safety of rofecoxib (Vioxx): lessons learned and unanswered questions: we need processes in place to follow up suspicions about serious adverse events, Med. J. Aust. 181, 524-525.
36. Layton, D., Heeley, E., Hughes, K., et al. (2003a). Comparison of the incidence rates of thromboembolic events reported for patients prescribed rofecoxib and meloxicam in general practice in England using prescription-event monitoring (PEM) data, Rheumatology (Oxford) 42, 1342-1353.
37. Layton, D., Hughes, K., Harris, S., et al. (2003b). Comparison of the incidence rates of thromboembolic events reported for patients prescribed celecoxib and meloxicam in general practice in England using Prescription-Event Monitoring (PEM) data, Rheumatology (Oxford) 42, 1354-1364.
38. Leung, A. T., Malmstrom, K., Gallacher, A. E., et al. (2002). Efficacy and tolerability profile of etoricoxib in patients with osteoarthritis: A randomized, double-blind, placebo and active-comparator controlled 12-week efficacy trial, Curr. Med. Res. Opin. 18, 49-58.
39. Levesque, L. E., Brophy, J. M. and Zhang, B. (2005). The risk for myocardial infarction with cyclooxygenase-2 inhibitors: a population study of elderly adults, Ann. Intern. Med. 142, 481-489.
40. Lewis, D. F., Ioannides, C. and Parke, D. V. (1990). A retrospective study of the molecular toxicology of benoxaprofen, Toxicology 65, 33-47.
41. McKenna, F., Arguelles, L., Burke, T., et al. (2002). Upper gastrointestinal tolerability of celecoxib compared with diclofenac in the treatment of osteoarthritis and rheumatoid arthritis, Clin. Exp. Rheumatol. 20, 35-43.
42. Morales, E. and Mucksavage, J. J. (2002). Cyclooxygenase-2 inhibitor-associated acute renal failure: case report with rofecoxib and review of the literature, Pharmacotherapy 22, 1317-1321.
43. Nussmeier, N. A., Whelton, A. A., Brown, M. T., et al. (2005). Complications of the COX-2 inhibitors parecoxib and valdecoxib after cardiac surgery, N. Engl. J. Med. 352, 1081-1091.
44. O'Brien, W. M. (1987). Rare adverse reactions to non-steroidal anti-inflammatory drugs, in: Side-effects of Anti-inflammatory Drugs. Part 1, Rainsford, K. D. and Velo, G. P. (Eds), pp. 73-104. MTP Press, Lancaster.
45. O'Brien, W. M. and Bagby, G. F. (1985). Rare adverse reactions to nonsteroidal antiinflammatory drugs, J. Rheumatol. 12, 562-567.
46. Pairet, M. and van Ryn, J. (Eds) (2004). COX-2 Inhibitors. Birkhäuser, Basel.
47. Prasit, P. and Riendeau, D. (1997). Selective cyclooxygenase-2 inhibitors, Annu. Rep. Med. Chem. 32, 211-220.
48. Prasit, P., Riendeau, D. and Chan, C. C. (2001). Discovery of Vioxx®(rofecoxib), in: Therapeutic Roles of Selective COX-2 Inhibitors, Vane, J. R. and Botting, R. M. (Eds), pp. 60-75. William Harvey Press, London.
49. Prescott, L. F. (1986). Liver damage with non-narcotic analgesics, Med. Toxicol. 1 (Suppl. 1), 44-56.
50. Psaty, B. M. and Furberg, C. D. (2005). COX-2 inhibitors - lessons in drug safety, N. Engl. J. Med. 352, 1133-1135.
51. Rainsford, K. D. (1987). Introduction and historical aspects of the side effects of anti-inflammatory analgesic drugs, in: Side Effects of Anti-Inflammatory Analgesic Drugs, Vol. 1, Rainsford, K. D. and Velo, G. P. (Eds), pp. 3-26. MTP Press, Lancaster.
52. Rainsford, K. D. (Ed.) (1997). Side Effects of Anti-inflammatory Drugs, Vol. 4. Kluwer, Dordrecht.
53. Rainsford, K. D. (1999). History and development of ibuprofen, in: Ibuprofen. A Critical Bibliographic Review, pp. 3-24. Taylor & Francis, London.
54. Rainsford, K. D. (2001). The ever-emerging anti-inflammatories. Have there been any real advances?, J. Physiol. (Paris) 95, 11-19.
55. Rainsford, K. D. (2003). Pharmacology and toxicology of COX-2 inhibitors, in: COX-2 Inhibitors, Milestones in Drug Therapy Series, Pairet, M. and van Ryn, J.-A. (Eds), pp. 67-131. Birkhäuser, Basel.
56. Rainsford, K. D. (2004). Inhibitors of eicosanoids, in: The Eicosanoids, Curtis-Prior, P. B. (Ed.), pp. 189-210. Wiley, Edinburgh.
57. Rawson, N. S., Nourjah, P., Grosser, S. C., et al. (2005). Factors associated with celecoxib and rofecoxib utilization, Ann. Pharmacother. 39, 597-602.
58. Reinhold, S. W., Fischereder, M., Riegger, G. A., et al. (2003). Acute renal failure after administration of a single dose of a highly selective COX-2 inhibitor, Clin. Nephrol. 60, 295-296.
59. Savage, R. (2005). Cyclo-oxygenase-2 inhibitors: when should they be used in the elderly?, Drugs Aging 22, 185-200.
60. Schoenfeld, P. (2001). An evidence-based approach to the gastrointestinal safety profile of COX-2 selective anti-inflammatories, Gastroenterol. Clin. North Am. 30, 1027-1044.
61. Silverstein, F. E., Faich, G., Goldstein, J. L., et al. (2000). Gastrointestinal toxicity with celecoxib vs nonsteroidal anti-inflammatory drugs for osteoarthritis and rheumatoid arthritis: the CLASS study: A randomized controlled trial. Celecoxib Long-term Arthritis Safety Study, J. Am. Med. Ass. 284, 1247-1255.
62. Solomon, D. H., Schneeweiss, S., Glynn, R. J., et al. (2004). Relationship between selective cyclooxygenase-2 inhibitors and acute myocardial nfarction in older adults, Circulation 109, 2068-2073.
63. Solomon, S. D., McMurray, J. J., Pfeffer, M. A., et al. (2005). Cardiovascular risk associated with celecoxib in a clinical trial for colorectal adenoma prevention, N. Engl. J. Med. 352, 1071-1080.
64. Stichtenoth, D. O. and Frölich, J. C. (2003). The second generation of COX-2 inhibitors: what advantages do the newest offer?, Drugs 63, 33-45.
65. Szalat, A., Krasilnikov, I., Bloch, A., et al. (2004). Acute renal failure and interstitial nephritis in a patient treated with rofecoxib: case report and review of the literature, Arthritis Rheum. 51, 670-673.
66. Topol, E. J. (2004). Failing the public health - rofecoxib, Merck, and the FDA, N. Engl. J. Med. 351, 1707-1709.
67. Topol, E. J. (2005). Arthritis medicines and cardiovascular events - "House of Coxibs", J. Am. Med. Ass. 293, 366-358.
68. US Food and Drug Administration, Joint Meeting of the Arthritis Advisory Committee and the Drug Safety and Risk Management Committee (2005). Minutes of the joint meeting, February 16, 17 and 18, 2005. Accessible online at http://www.fda.gov/ohrms/dockets/ac/minutes/2005-4-90MI_final.doc 04-05-2005 (accessed 25/7/05).
69. US Food and Drug Administration, FDA Public Health Advisory (2005). FDA announces important changes and additional warnings for COX-2 selective and non-selective non-steroidal anti-inflammatory drugs (NSAIDs). Accessible online at http://www.fda.gov/cder/drug/advisory/COX2.htm (accessed 25/7/05).
70. Vane, J. R. and Bolting, R. M. (Eds) (2001). Therapeutic Roles of Selective COX-2 Inhibitors. William Harvey Press, London.
71. Walter, M. R, Jacob, R. F., Day, C. A., et al. (2004). Sulfone COX-2 inhibitors increase susceptibility of human LDL and plasma to oxidative modification: comparison to sulfonamide COX-2 inhibitors and NSAIDs, Atherosclerosis 177, 235-243.
72. Watson, D. J., Bolognese, J. A., Yu, C., et al. (2004). Use of gastroprotective agents and discontinuations due to dyspepsia with the selective cyclooxygenase-2 inhibitor etoricoxib compared with non-selective NSAIDs, Curr. Med. Res. Opin. 20, 1899-1908.
73. Weber, J. C. P. (1984). Epidemiology of adverse reactions to nonsteroidal antiinflammatory drugs, in: Side-Effects of Antiinflammatory/Analgesic Drugs. Advances in Inflammation Research, Vol. 6, Rainsford, K. D. and Velo, G. P. (Eds), pp. 1-7. Raven Press, New York, NY.
74. Whelton, A., Fort, J. G., Puma, J. A., et al. (2001). Cyclooxygenase-2-specific inhibitors and cardiorenal function: a randomised, controlled trial of celecoxib and rofecoxib in older hypertensive osteoarthritis patients, Am. J. Ther. 8, 85-95
75. (erratum Am. J. Ther. 8, 220).
76. White, W. B., Faich, G., Borer, J. S., et al. (2003). Cardiovascular tnrombotic events in arthritis trials of the cyclooxygenase-2 inhibitor celecoxib, Am. J. Cardiol. 92, 411-418.
77. Wolf, G., Porth, J. and Stahl, R. A. (2000). Acute renal failure associated with rofecoxib, Ann. Intern. Med. 133, 394.
78. Wong, D., Wang, M., Cheng, Y., et al. (2005). Cardiovascular hazard and non-steroidal anti-inflammatory drugs, Curr. Opin. Pharmacol. 5, 204-210.
79. Woywodt, A. A., Schwarz, A., Mengel, M., et al. (2001). Nephrotoxicity of selective COX-2 inhibitors, J. Rheumatol. 28, 2133-2135.
80. Yuan, Y. and Hunt, R. H. (2003). Assessment of the safety of cyclo-oxygenase-2 inhibitors: where are we in 2003?, Inflammopharmacology 11, 337-354.